These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16517843)

  • 1. Analysis of mutations within the 5' untranslated region, interferon sensitivity region, and PePHD region as a function of response to interferon therapy in hepatitis C virus-infected patients in India.
    Gupta R; Subramani M; Khaja MN; Madhavi C; Roy S; Habibullah CM; Das S
    J Clin Microbiol; 2006 Mar; 44(3):709-15. PubMed ID: 16517843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
    Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
    Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.
    Muñoz de Rueda P; Casado J; Patón R; Quintero D; Palacios A; Gila A; Quiles R; León J; Ruiz-Extremera A; Salmerón J
    J Virol; 2008 Jul; 82(13):6644-53. PubMed ID: 18448540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment.
    Berg T; Mas Marques A; Höhne M; Wiedenmann B; Hopf U; Schreier E
    Hepatology; 2000 Dec; 32(6):1386-95. PubMed ID: 11093746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Laufer N; Torres C; Cassino L; Reynoso R; Quarleri J
    Antiviral Res; 2012 Aug; 95(2):72-81. PubMed ID: 22683884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
    Murphy MD; Rosen HR; Marousek GI; Chou S
    Dig Dis Sci; 2002 Jun; 47(6):1195-205. PubMed ID: 12064791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy.
    Sarrazin C; Bruckner M; Herrmann E; Rüster B; Bruch K; Roth WK; Zeuzem S
    Virology; 2001 Oct; 289(1):150-63. PubMed ID: 11601926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in two PKR-binding domains in chronic hepatitis C of genotype 3a and correlation with viral loads and interferon responsiveness.
    Yokozaki S; Katano Y; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
    J Med Virol; 2011 Oct; 83(10):1727-32. PubMed ID: 21837788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response.
    Sarrazin C; Kornetzky I; Rüster B; Lee JH; Kronenberger B; Bruch K; Roth WK; Zeuzem S
    Hepatology; 2000 Jun; 31(6):1360-70. PubMed ID: 10827164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C.
    Puig-Basagoiti F; Sáiz JC; Forns X; Ampurdanès S; Giménez-Barcons M; Franco S; Sánchez-Fueyo A; Costa J; Sánchez-Tapias JM; Rodés J
    J Med Virol; 2001 Sep; 65(1):35-44. PubMed ID: 11505441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.
    Vuillermoz I; Khattab E; Sablon E; Ottevaere I; Durantel D; Vieux C; Trepo C; Zoulim F
    J Med Virol; 2004 Sep; 74(1):41-53. PubMed ID: 15258967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome.
    Gaudy C; Lambelé M; Moreau A; Veillon P; Lunel F; Goudeau A
    J Clin Microbiol; 2005 Feb; 43(2):750-4. PubMed ID: 15695675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations.
    Pawlotsky JM; Germanidis G; Neumann AU; Pellerin M; Frainais PO; Dhumeaux D
    J Virol; 1998 Apr; 72(4):2795-805. PubMed ID: 9525599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.
    Hung CH; Lee CM; Lu SN; Lee JF; Wang JH; Tung HD; Chen TM; Hu TH; Chen WJ; Changchien CS
    J Viral Hepat; 2003 Mar; 10(2):87-94. PubMed ID: 12614464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of the interferon sensitivity-determining region (ISDR) correlate with the complexity of hypervariable region (HVR)-1 in the Japanese variant of hepatitis C virus (HCV) type 1b.
    Nakano I; Fukuda Y; Katano Y; Toyoda H; Hayashi K; Kumada T; Nakano S
    J Med Virol; 2004 Sep; 74(1):54-61. PubMed ID: 15258968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection.
    Polyak SJ; McArdle S; Liu SL; Sullivan DG; Chung M; Hofgärtner WT; Carithers RL; McMahon BJ; Mullins JI; Corey L; Gretch DR
    J Virol; 1998 May; 72(5):4288-96. PubMed ID: 9557719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the E2 and NS5A regions in patients infected with hepatitis C virus genotype 1a and their correlation with response to treatment.
    Yahoo N; Sabahi F; Shahzamani K; Malboobi MA; Jabbari H; Sharifi H; Mousavi-Fard SH; Merat S
    J Med Virol; 2011 Aug; 83(8):1332-7. PubMed ID: 21678437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in carboxy-terminal part of E2 including PKR/eIF2alpha phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: their correlation with response to interferon monotherapy and viral load.
    Ukai K; Ishigami M; Yoshioka K; Kawabe N; Katano Y; Hayashi K; Honda T; Yano M; Goto H
    World J Gastroenterol; 2006 Jun; 12(23):3722-8. PubMed ID: 16773689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mutation analysis of ISDR and V3 domains of hepatitis C virus NS5A region before interferon therapy with or without ribavirin].
    Veillon P; Payan C; Gaudy C; Goudeau A; Lunel F
    Pathol Biol (Paris); 2004 Nov; 52(9):505-10. PubMed ID: 15531113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin.
    Jardim AC; Yamasaki LH; de Queiróz AT; Bittar C; Pinho JR; Carareto CM; Rahal P; Mello IM
    Infect Genet Evol; 2009 Jul; 9(4):689-98. PubMed ID: 19063998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.